Brief: Pulmatrix Reports 2022 Net Loss Per Share Of $5.46
Pulmatrix Inc expected to post a loss of $1.44 a share - Earnings Preview
Brief: Pulmatrix Announces First Patient Dosed In Phase 2B Study Of Pur1900 For Treatment Of Allergic Bronchopulmonary Aspergillosis In Subjects With Asthma
Brief: Pulmatrix Announces Positive Top Line Results From Phase 1 Study With PUR3100
Pulmatrix Inc reports results for the quarter ended in September - Earnings Summary
Brief: Pulmatrix Announces Third Quarter Results
Pulmatrix Inc expected to post a loss of $1.51 a share - Earnings Preview
Brief: Pulmatrix Announces Patient Dosing Completed For Its Novel Inhaled Therapy Pur3100 For Acute Migraine
Pulmatrix Inc reports results for the quarter ended in June - Earnings Summary
Brief: Pulmatrix Announces Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: Pulmatrix Announces First Subject Dosed In Phase 1 Study Of Pur3100 For Acute Migraine
Brief: Pulmatrix Announces First Quarter 2022 Financial Results
Pulmatrix Inc expected to post a loss of $1.41 a share - Earnings Preview
Brief: Pulmatrix Inc Says On April 14, Appointed Peter Ludlum As Interim CFO Effective As Of April 18, 2022
Pulmatrix Inc reports results for the quarter ended in December - Earnings Summary
Brief: Pulmatrix Announces Q4 Results, Provides Corporate Update
Brief: Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 In Patients With Stable COPD
Pulmatrix Inc expected to post a loss of $1.60 a share - Earnings Preview
Brief: Pulmatrix Regains Compliance With Nasdaq Listing Requirements